Exhibit 99.1

              TRANSGENOMIC RECEIVES LETTER FROM NASDAQ STOCK MARKET

OMAHA, Neb., February 22, 2006 / -- Transgenomic Inc. (Nasdaq: TBIO) announced
today that it had received a letter from the staff of the Listing Qualifications
Department of The Nasdaq Stock Market on February 15, 2006, indicating that the
Company does not comply with the $1.00 minimum bid price requirement for
continued listing set forth in Marketplace Rule 4450(a)(5). Therefore, in
accordance with Marketplace Rule 4450(e)(2), Transgenomic will have 180 days, or
until August 14, 2006, to regain compliance. If, at any time before August 14,
2006, the bid price of the Company's common stock closes at or above $1.00 per
share for at least ten consecutive business days, Transgenomic will have
achieved compliance with the $1.00 minimum bid price rule. The Nasdaq staff may,
in its sole discretion, require the Company to maintain a closing bid price of
at least $1.00 per share for a longer period before determining that the Company
has demonstrated the ability to maintain long-term compliance.

ABOUT TRANSGENOMIC

Transgenomic is a global company that provides versatile and innovative products
and services to the medical research and pharmaceutical markets. Transgenomic's
WAVE Systems are specifically designed for use in genetic variation detection.
They have broad applicability to genetic research and molecular diagnostics. The
emerging pursuit of personalized medicine is driving the ongoing need to detect
new, uncharacterized mutations and genetic polymorphisms. The high analytical
sensitivity of the WAVE System makes it a uniquely enabling technology for the
advancement of personalized medicine. To date there have been over one thousand
systems installed in over 30 countries around the world. In addition to the sale
of systems and consumables Transgenomic provides services to pharmaceutical and
biopharmaceutical companies in preclinical and clinical development of targeted
therapeutics. For more information about the innovative genomics research tools
developed and marketed by Transgenomic, please visit the company's Web site at
www.transgenomic.com.

TRANSGENOMIC CAUTIONARY STATEMENTS

Certain statements in this press release constitute "forward-looking statements"
of Transgenomic within the meaning of the Private Securities Litigation Reform
Act of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements include, but are not limited to, those
with respect to management's current views and estimates of future economic
circumstances, industry conditions, company performance and financial results,
including the future trading price of the Company's common stock and the future
listing of the Company's common stock on Nasdaq. The known risks, uncertainties
and other factors affecting these forward-looking statements are described from
time to time in Transgenomic's reports to the Securities and Exchange
Commission. Any change in such factors, risks and uncertainties may cause the
actual results, events and performance to differ materially from those referred
to in such statements. Accordingly, the company claims the protection of the
safe harbor for forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995 with respect to all statements contained in this
press release. All information in this press release is as of the date of the
release and Transgenomic does not undertake any duty to update this information,
including any forward-looking statements, unless required by law.

For confirmation of release or further information, please contact:

         Mitchell L. Murphy
         Transgenomic Inc.
         402-452-5418
         mmurphy@transgenomic.com